Duration and dosing of Proton Pump Inhibitors associated with high incidence of chronic kidney disease in population-based cohort
dc.contributor.author
dc.date.accessioned
2020-10-05T09:36:43Z
dc.date.available
2020-10-05T09:36:43Z
dc.date.issued
2018-10-17
dc.identifier.uri
dc.description.abstract
Proton Pump Inhibitors (PPIs) have been associated with chronic kidney disease (CKD). Our objective was to quantify the association between PPI use and incident CKD in a population-based cohort.
Methods and findings
We used a population-based retrospective cohort, including people aged 15 years or over, between January 1, 2005 and December 31, 2012. PPI use was measured in a follow-up session by recording prescriptions. Incident CKD was defined as an estimated glomerular filtration rate < 60 ml/ min/1.73 m2 and/or urinary albumin level to creatinine level ≥ 30 mg/g, in two or more determinations over a period of at least 3 months of the follow-up. Proton Pump Inhibitor use was associated with incident CKD in analysis adjusted for different clinical variables (Hazard Ratio (HR) 1.18; 95% CI 1.04–1.51) in individuals who used PPI in the basal visit (HR 1.37; 95% CI 1.25–1.50) and in those who started to use PPI during the follow-up. High doses of PPI increased the risk of incident CKD (HR 1.92; 95%CI 1.00–6.19) for any type of exposure to PPIs (HR 2.40; 95%CI 1.65–3.46) and for individuals who used high doses throughout the follow-up. This risk of incident CKD increased after three months’ exposure to PPIs, (HR1.78; 95% CI 1.39–2.25) between the third and sixth months and (HR 1.30; 95%CI 1.07–1.72) after the sixth month.
Conclusions
PPI use is associated with a higher risk of incident CKD. This association is greater for high doses and becomes apparent after three months’ exposure
dc.description.sponsorship
This work was partly funded by the research project PI15/00140 from FIS, ‘Instituto de Salud Carlos III’, ISCIII, Spanish Ministry of Economy and Competitiveness and by the project ‘Grant to improve the scientific productivity of the research groups of the University of Girona 2016-2018’ (MPCUdG2016
dc.format.mimetype
application/pdf
dc.language.iso
eng
dc.publisher
Public Library of Science
dc.relation.isformatof
Reproducció digital del document publicat a: https://doi.org/10.1371/journal.pone.0204231
dc.relation.ispartof
PLoS ONE, 2017, vol. 13, núm. 10, p. e0204231
dc.relation.ispartofseries
Articles publicats (D-EC)
dc.rights
Attribution 4.0 International
dc.rights.uri
dc.subject
dc.title
Duration and dosing of Proton Pump Inhibitors associated with high incidence of chronic kidney disease in population-based cohort
dc.type
info:eu-repo/semantics/article
dc.rights.accessRights
info:eu-repo/semantics/openAccess
dc.type.version
info:eu-repo/semantics/publishedVersion
dc.identifier.doi
dc.identifier.idgrec
028992
dc.type.peerreviewed
peer-reviewed
dc.identifier.eissn
1932-6203